TB-500, AOD-9604, LL-37, KPV, ARA-290: separating peptide reality from TikTok reconstitution theater

What did @alycepeptide actually say?

Honestly? Not much that can be evaluated. The transcript captured from this video reads: "So I don't like the tone just hurt warm You shot it when I hurt you" — which appears to be a transcription error, likely garbled audio or background speech picked up instead of the creator's actual commentary. The caption lists five peptides: TB-500, AOD-9604, LL37, KPV, and ARA-290, and promises dosing and reconstitution guidance for each. But there is no evaluable claim in the transcript to fact-check directly. This review will instead assess what a video with this caption would typically claim, and what the evidence actually says about these five compounds.

Does the science back up the implied claims?

Reconstitution guidance for research peptides is a genuinely useful topic. The problem is that most peptides circulating in this space are not FDA-approved for human use, and dosing information shared on TikTok carries real risk. Each of the five peptides named here has a distinct evidence profile, and lumping them together in one "dose guide" flattens important differences.

• TB-500 (Thymosin Beta-4 fragment): Thymosin Beta-4 has shown wound-healing and anti-inflammatory effects in animal models and some small human trials (Goldstein et al., 2012, Annals of the New York Academy of Sciences). TB-500 is a synthetic fragment, not identical to the studied compound. No human RCTs support specific dosing protocols.
• AOD-9604: This fragment of human growth hormone was studied for obesity but failed Phase 3 trials for weight loss (Heffernan et al., 2001, Journal of Clinical Endocrinology and Metabolism). It is not approved anywhere for human use.
• LL37: An antimicrobial peptide with immune-modulating activity in vitro (Vandamme et al., 2012, Frontiers in Immunology). No approved human therapeutic use. Reconstitution and injection carry infection risk.
• KPV: A tripeptide derivative of alpha-MSH with anti-inflammatory activity in rodent gut models (Dalmasso et al., 2008, Journal of Proteome Research). Human data is essentially nonexistent.
• ARA-290: A non-hematopoietic erythropoietin analogue studied in small trials for neuropathic pain in sarcoidosis (Niesters et al., 2013, PLOS ONE). Promising but early-stage. Not approved for general use.

What did they get wrong (or right)?

Because the transcript is unreadable, we cannot confirm specific errors. What we can say is that the framing of this video — presenting reconstitution and dosing for five unapproved research peptides to a general TikTok audience — is itself a problem regardless of the specific words used. These are not interchangeable wellness supplements. LL37 injected incorrectly can cause serious immune reactions. AOD-9604 failed its primary clinical endpoints in human trials, a fact that often gets omitted when it is promoted as a fat-loss peptide. Credit where it is due: if the video actually walks through sterile reconstitution technique (bacteriostatic water, proper dilution math, avoiding contamination), that is practical harm-reduction information. But it cannot substitute for medical supervision.

What should you actually know?

None of the five peptides listed in this video's caption are FDA-approved for the uses typically promoted in peptide communities. That does not automatically mean they are useless, but it does mean the risk-benefit math is yours to bear without regulatory backstop. Reconstitution errors are a real source of harm: wrong diluent, wrong concentration, non-sterile technique, and improper storage can all degrade the compound or introduce infection risk. If you are considering any of these peptides, the conversation starts with a licensed clinician who can order labs, assess contraindications, and monitor response. A TikTok video, however well-intentioned, is not that conversation. The FDA has repeatedly warned that peptides sold as "research chemicals" are not subject to manufacturing oversight, meaning purity and concentration are not guaranteed (FDA, 2023, Import Alert 66-71).